Best Diuretic for CAD, Preserved EF, and History of CVA
For a patient with coronary artery disease, preserved ejection fraction heart failure (HFpEF), and prior stroke, a thiazide or thiazide-like diuretic (chlorthalidone or hydrochlorothiazide) is the preferred first-line diuretic choice, particularly if hypertension is present with mild fluid retention. If significant congestion exists requiring more potent diuresis, loop diuretics should be used, with torsemide potentially preferred over furosemide due to superior bioavailability 1.
Clinical Reasoning
Why Thiazides for This Patient Profile
Your patient sits at the intersection of three major cardiovascular conditions, and the diuretic choice must address all three:
For CAD: Guidelines recommend ACE inhibitors, ARBs, or beta-blockers as foundational therapy 2, 3, 4. When blood pressure control requires a diuretic, thiazides are appropriate first-line agents 3, 5.
For HFpEF: Unlike heart failure with reduced ejection fraction (HFrEF), no diuretic has proven mortality benefit in HFpEF 1, 6. Diuretics serve purely for symptom control and congestion management. The 2022 AHA/ACC/HFSA guidelines state that thiazide diuretics may be considered in patients with hypertension and heart failure with mild fluid retention 1.
For Prior CVA: The strongest evidence supports an ACE inhibitor plus thiazide diuretic combination for secondary stroke prevention 7, 4, 5. This combination is explicitly preferred in cerebrovascular disease patients 5.
Loop Diuretics: When and Which One
Loop diuretics become necessary when:
- Significant volume overload or congestion is present
- Thiazides prove inadequate for symptom control
- The patient has renal impairment (eGFR <30 mL/min) 1
Among loop diuretics, while furosemide remains most commonly used, torsemide offers advantages 1:
- Superior oral bioavailability (80-100% vs 40-50% for furosemide)
- Longer duration of action (12-16 hours vs 6-8 hours)
- More predictable absorption, particularly important in HFpEF where gut edema may impair furosemide absorption
Initial dosing for loop diuretics 1:
- Torsemide: 10-20 mg once daily
- Furosemide: 20-40 mg once or twice daily
- Bumetanide: 0.5-1.0 mg once or twice daily
Critical Caveats for HFpEF
HFpEF responds differently to aggressive diuresis than HFrEF. A 2021 study demonstrated that high-dose furosemide strategies in HFpEF significantly increased creatinine and cystatin C without improving net fluid loss, weight loss, or clinical outcomes—unlike in HFrEF where aggressive diuresis proved beneficial 8. This means:
- Use the lowest effective diuretic dose to maintain euvolemia 1
- Avoid overly aggressive diuresis which can precipitate hypotension, renal dysfunction, and reduced cardiac output in HFpEF
- Monitor closely for signs of overdiuresis: orthostatic hypotension, worsening renal function, fatigue
Blood Pressure Targets Matter
Target blood pressure should be <130/80 mmHg in this patient 4. However, exercise caution with diastolic pressures—avoid dropping DBP below 60 mmHg in CAD patients, as this may increase myocardial infarction risk 3.
Combination Diuretic Therapy
If congestion persists despite optimized loop diuretic dosing:
Add metolazone 2.5 mg for sequential nephron blockade 1, 9. A 2024 study showed furosemide plus metolazone produced the highest natriuresis (4,691 mg sodium vs 3,835 mg with furosemide alone) 9. However, worsening renal function occurred in 39% with metolazone vs 16% with furosemide alone 9.
Consider acetazolamide 500 mg IV as an alternative to metolazone 9, 10. This combination showed only 2.6% incidence of worsening renal function while still providing effective diuresis 9.
Avoid combining ACE inhibitor with ARB in CAD patients without systolic heart failure 2.
The Foundation: Not Just Diuretics
Diuretics should never be used in isolation 1. This patient requires:
- SGLT2 inhibitor (dapagliflozin or empagliflozin)—the only proven disease-modifying therapy for HFpEF 6
- ACE inhibitor or ARB for CAD and stroke prevention 3, 4, 5
- Beta-blocker if prior MI or for rate control if atrial fibrillation present 3
- Statin therapy with LDL-C target <55 mg/dL for CAD 4
- Antiplatelet therapy once blood pressure controlled 3, 5